Glaukos Corp
Open
SectorGezondheidszorg
167.08 -1.75
Overzicht
Wijziging aandelenprijs
24u
Min
167.45
Max
175.18
Inkomsten | 1.4M -18M |
|---|---|
Verkoop | 35M 186M |
EPS | -0.14 |
Winstmarge | -9.901 |
Werknemers | 1,094 |
EBITDA | -1.6M -6.9M |
Volgende Winsten | 28 okt 2026 |
|---|
Marktkapitalisatie | 1.5B 10B |
|---|---|
Vorige openingsprijs | 168.83 |
Vorige sluitingsprijs | 167.08 |
Nieuwssentiment
By Acuity
64%
36%
300 / 339 Rangschikking in Healthcare
Glaukos Corp Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Glaukos Corp Prognose
Sentiment
By Acuity
300 / 339 Rangschikking in Gezondheidszorg
Nieuwssentiment
Bullish Bewijs
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Onder gemiddelde
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.